Anabel Sorolla

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1551583/publications.pdf

Version: 2024-02-01

48 papers	1,199 citations	394421 19 h-index	395702 33 g-index
49 all docs	49 docs citations	49 times ranked	2092 citing authors

#	Article	IF	Citations
1	Applications of CRISPR technology to lung cancer research. European Respiratory Journal, 2022, 59, 2102610.	6.7	6
2	Cell-Free DNA Concentration and Pattern Fragmentation in Pleural Fluid and Plasma to Detect Malignant Effusions. Annals of the American Thoracic Society, 2022, 19, 854-856.	3.2	4
3	Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?. Cancers, 2022, 14, 1101.	3.7	8
4	The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer. Nature Communications, 2021, 12, 1920.	12.8	19
5	Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions. Cancers, 2021, 13, 2798.	3.7	20
6	An N-ethyl-N-Nitrosourea Mutagenesis Screen in Mice Reveals a Mutation in Nuclear Respiratory Factor 1 (Nrf1) Altering the DNA Methylation State and Correct Embryonic Development. Animals, 2021, 11, 2103.	2.3	1
7	Design and Characterization of a Cell-Penetrating Peptide Derived from the SOX2 Transcription Factor. International Journal of Molecular Sciences, 2021, 22, 9354.	4.1	4
8	Microenvironmental Reactive Oxygen Species in Colorectal Cancer: Involved Processes and Therapeutic Opportunities. Cancers, 2021, 13, 5037.	3.7	20
9	Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics. Oncogene, 2020, 39, 1167-1184.	5.9	61
10	Determinants of Sensitivity to Radiotherapy in Endometrial Cancer. Cancers, 2020, 12, 1906.	3.7	15
11	Prognostic Factors Involved in the Epithelialâ€“Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 3330.	3.7	5
12	Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer. Npj Precision Oncology, 2020, 4, 24.	5.4	86
13	Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment. Expert Opinion on Drug Delivery, 2020, 17, 1597-1613.	5.0	22
14	From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds. Biomolecules, 2020, 10, 248.	4.0	34
15	Sensitizing endometrial cancer to ionizing radiation by multi-tyrosine kinase inhibition. Journal of Gynecologic Oncology, 2020, 31, e29.	2.2	6
16	Cell Culture Confluency as a Potential Factor in Biological Effects of Millimetre Wave Radiation in In Vitro Experiments. , 2020, , .		0
17	Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers. Oncogene, 2019, 38, 140-150.	5.9	55
18	Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 20, 102003.	3.3	36

#	Article	IF	Citations
19	Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers. Chemical Science, 2019, 10, 7718-7727.	7.4	37
20	Utilisation of MMW Radiation to Facilitate Apoptosis in Triple Negative Breast Cancer Cell Lines via TRPV1 Receptor Sensitization. , 2019, , .		1
21	Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy. Langmuir, 2018, 34, 15343-15349.	3.5	120
22	Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells. Marine Drugs, 2018, 16, 361.	4.6	19
23	Crambescidin 800, Isolated from the Marine Sponge Monanchora viridis, Induces Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells. Marine Drugs, 2018, 16, 53.	4.6	30
24	Melanocyte transformation requires complete loss of all pocket protein function via a mechanism that mitigates the need for MAPK pathway activation. Oncogene, 2017, 36, 3789-3795.	5.9	2
25	Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system. Oncotarget, 2016, 7, 60535-60554.	1.8	61
26	Sensitizing basal-like breast cancer to chemotherapy using nanoparticles conjugated with interference peptide. Nanoscale, 2016, 8, 9343-9353.	5.6	23
27	Abstract P2-06-01: Characterisation of C11orf67, an oncogenic driver in a new subtype of aggressive endocrine receptor positive breast cancer. , 2016, , .		0
28	<scp>ATF</scp>2 alters melanocyte response and macrophage recruitment in <scp>UV</scp>â€irradiated neonatal mouse skin. Pigment Cell and Melanoma Research, 2015, 28, 481-484.	3.3	4
29	Identification of novel hypomorphic and null mutations in Klf1 derived from a genetic screen for modifiers of Î±-globin transgene variegation. Genomics, 2015, 105, 116-122.	2.9	11
30	Characterisation of Novel Hypomorphic and Null Mutations in Klf1 Derived from a Genetic Screen for Modifiers of a-Globin Transgene Variegation. Blood, 2015, 126, 3329-3329.	1.4	0
31	Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation. PLoS ONE, 2014, 9, e92764.	2.5	3
32	An ENU mutagenesis screen identifies novel and known genes involved in epigenetic processes in the mouse. Genome Biology, 2013, 14, R96.	9.6	74
33	Combination of Vorinostat and caspaseâ€8 inhibition exhibits high antiâ€tumoral activity on endometrial cancer cells. Molecular Oncology, 2013, 7, 763-775.	4.6	16
34	Functional expression of voltageâ€gated calcium channels in human melanoma. Pigment Cell and Melanoma Research, 2012, 25, 200-212.	3.3	47
35	Nuevas dianas terapÃ©uticas en el melanoma. Actas Dermo-sifiliogrÃ¡ficas, 2012, 103, 579-590.	0.4	12
36	New Therapeutic Targets in Melanoma. Actas Dermo-sifiliogrÃ¡ficas, 2012, 103, 579-590.	0.4	11

#	Article	IF	Citations
37	Blockade of NFÎºB activity by Sunitinib increases cell death in Bortezomibâ€treated endometrial carcinoma cells. Molecular Oncology, 2012, 6, 530-541.	4.6	29
38	Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. International Journal of Cancer, 2012, 130, 967-978.	5.1	35
39	Nuclear factor-ÎºB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1Î± independent manner. Laboratory Investigation, 2011, 91, 859-871.	3.7	33
40	The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. European Journal of Cancer, 2010, 46, 836-850.	2.8	43
41	Expression of Somatostatin Receptors in Human Melanoma Cell Lines: Effect of Two Different Somatostatin Analogues, Octreotide and SOM230, on Cell Proliferation. Journal of International Medical Research, 2009, 37, 1813-1822.	1.0	19
42	CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene, 2008, 27, 2513-2524.	5.9	48
43	Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. British Journal of Dermatology, 2008, 158, 496-504.	1.5	41
44	Targeted therapies in gynecologic cancers and melanoma. Seminars in Diagnostic Pathology, 2008, 25, 262-273.	1.5	8
45	Loss of Heterozygosity in Endometrial Carcinoma. International Journal of Gynecological Pathology, 2008, 27, 305-317.	1.4	18
46	Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anti-Cancer Drugs, 2008, 19, 115-124.	1.4	51
47	Nuevas dianas terapÃ©uticas en el melanoma. Piel, 2007, 22, 205-211.	0.0	0
48	Targeting the Proteasome in Melanoma. , 0, , .		0